| dc.creator |
BİNDAL, Ahmet; ŞANLIURFA EĞİTİM ARAŞTIRMA HASTANESİ |
|
| dc.date |
2021-09-13T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:46:53Z |
|
| dc.date.available |
2021-12-03T11:46:53Z |
|
| dc.identifier |
https://dergipark.org.tr/tr/pub/sdutfd/issue/64881/982218 |
|
| dc.identifier |
10.17343/sdutfd.982218 |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/94107 |
|
| dc.description |
ObjectiveWe aimed to observe the effect of pulse steroidtherapy used in the hyperinflammatory phase thatoccurs during the course of the COVID-19 diseaseon the inflammatory markers and clinical conditionsof the patients.Materials and MethodsIn this study, 30 patients with positive COVID-19 PCR(polymerase chain reaction) test who were treatedwith pulse steroid (high-dose methylprednisolone)due to the hyperinflammatory phase were evaluated.The clinical conditions and inflammatory markersof the patients were retrospectively analyzed.Patients were evaluated in terms of age, gender,intubation status, clinical improvement, discharge,mortality rate, 24th, 48th, 72nd hours and 7th daysafter treatment initiation, C-reactive protein (CRP),procalcitonin, ferritin, oxygen saturation values,lymphocyte count.ResultsA total of 30 patients; 21 male and 9 female, whoreceived pulse steroid therapy were examined. Themedian age was calculated as 66 [31-88]. In thestudy, 15 (50%) patients died, of which 11 were maleand 4 were female. When the survived and deceasedpatients were compared, it was observed that thevalues of ferritin, CRP procalcitonin measured at72 hours and 7 days after pulse steroid treatmentdecreased significantly in the survived patient group.(72nd hour p-values=0.01-0.08- |
|
| dc.description |
COVID-19 hastalığının süreci esnasında ortaya çıkanhiperinflamatuar fazda kullanılan pulse steroid tedavisininhastaların inflamatuar belirteçlerine ve klinikdurumlarına etkisini gözlemlemeyi amaçladık.Gereç ve YöntemBu çalışmada hiperinflamatuar faz nedeniyle pulsesteroid (yüksek doz metilprednizolon) ile tedavi edilen,COVID-19 PCR (polimeraz zincir reaksiyonu)testi pozitif olan 30 hasta değerlendirildi. Hastalarınklinik durumları ve inflamatuar belirteçleri retrospektifolarak incelendi. Hastalar; yaş, cinsiyet, entübasyondurumu, klinik düzelme, taburculuk, mortalite oranı,tedavi başlangıcından 24-48-72. saat ve 7. günde ölçülen;C-reaktif protein (CRP), prokalsitonin, ferritin,oksijen saturasyon değeri ve lenfosit sayısı açısındandeğerlendirildi.BulgularToplamda pulse steroid tedavisi alan 21 erkek, 9 kadınolmak üzere 30 hasta incelendi. Ortanca yaş 66[31-88] olarak hesaplandı. Çalışmada 15 (%50) hastavefat etmiş olup, bunun 11’i erkek, 4’ü kadın hastaydı.Yaşayan ve ölen hastalar karşılaştırıldıklarında; pulsesteroid tedavisi sonrası 72. saat ve 7. günde ölçülenferritin, CRP, prokalsitonin değerlerinin yaşayan hastagrubunda anlamlı olarak azaldığı görüldü. (sırasıyla72. saat p= 0,01; 0,08 ; |
|
| dc.format |
application/pdf |
|
| dc.language |
tr |
|
| dc.publisher |
Süleyman Demirel Üniversitesi |
|
| dc.publisher |
Süleyman Demirel University |
|
| dc.relation |
https://dergipark.org.tr/tr/download/article-file/1922437 |
|
| dc.source |
Volume: 28, Issue: 3
479-486 |
en-US |
| dc.source |
1300-7416 |
|
| dc.source |
2602-2109 |
|
| dc.source |
SDÜ Tıp Fakültesi Dergisi |
|
| dc.subject |
COVID-19,pulse steroid therapy,CRP,ferritin |
|
| dc.subject |
COVİD-19,pulse steroid tedavisi,CRP,ferritin |
|
| dc.title |
EFFECT OF PULSE STEROID THERAPY ON MORTALITY IN SEVERE COVID-19 PNEUMONIA |
en-US |
| dc.title |
AĞIR COVID-19 PNÖMONİSİNDE PULSE STEROİD TEDAVİSİNİN MORTALİTE ÜZERİNE ETKİSİ |
tr-TR |
| dc.type |
info:eu-repo/semantics/article |
|
| dc.citation |
1. The epidemiological characteristics of an outbreak of 2019
novel coronavirus diseases (COVID-19) in China. Zhonghua
liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
2020;41(2):145-51. PubMed PMID: 32064853. Epub
2020/02/18. |
|
| dc.citation |
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical
features of patients infected with 2019 novel coronavirus in Wuhan,
China. Lancet (London, England). 2020;395(10223):497-
506. PubMed PMID: 31986264. Pubmed Central PMCID:
PMC7159299. Epub 2020/01/28. eng. |
|
| dc.citation |
3. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR,
Nalla AK, et al. COVID-19 in Critically Ill Patients in the Seattle
Region - Case Series. The New England journal of medicine.
2020;382(21):2012-22. PubMed PMID: 32227758. Pubmed
Central PMCID: PMC7143164. Epub 2020/04/01. eng. |
|
| dc.citation |
4. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed
states: A clinical-therapeutic staging proposal.
The Journal of heart and lung transplantation : the official publication
of the International Society for Heart Transplantation.
2020;39(5):405-7. PubMed PMID: 32362390. Pubmed Central
PMCID: PMC7118652. Epub 2020/05/05. eng. |
|
| dc.citation |
5. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS,
Manson JJ. COVID-19: consider cytokine storm syndromes
and immunosuppression. Lancet (London, England).
2020;395(10229):1033-4. PubMed PMID: 32192578. Pubmed
Central PMCID: PMC7270045. Epub 2020/03/21. eng. |
|
| dc.citation |
6. Russell CD, Millar JE, Baillie JK. Clinical evidence does not
support corticosteroid treatment for 2019-nCoV lung injury.
Lancet 2020;395(10223):473-5. PubMed PMID: 32043983. Pubmed
Central PMCID: PMC7134694. Epub 2020/02/12. eng. |
|
| dc.citation |
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical
Characteristics of 138 Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China. Jama.
2020;323(11):1061-9. PubMed PMID: 32031570. Pubmed
Central PMCID: PMC7042881. Epub 2020/02/08. eng. |
|
| dc.citation |
8. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The
use of anti-inflammatory drugs in the treatment of people with
severe coronavirus disease 2019 (COVID-19): The Perspectives
of clinical immunologists from China. Clinical immunology.
2020;214:108393. PubMed PMID: 32222466. Pubmed Central
PMCID: PMC7102614. Epub 2020/03/31. eng. |
|
| dc.citation |
9. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal
DN. Pharmaco-Immunomodulatory Therapy in COVID-19.
Drugs. 2020;80(13):1267-92. PubMed PMID: 32696108. Pubmed
Central PMCID: PMC7372203 Epub 2020/07/23. eng. |
|
| dc.citation |
10. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment
of severe COVID-19 patients with tocilizumab. Proceedings
of the National Academy of Sciences of the United States
of America. 2020;117(20):10970-5. PubMed PMID: 32350134.
Pubmed Central PMCID: PMC7245089. Epub 2020/05/01. eng. |
|
| dc.citation |
11. Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti
G, Mak SM, et al. Persistent Post-COVID-19 Interstitial Lung
Disease. An Observational Study of Corticosteroid Treatment.
Annals of the American Thoracic Society. 2021;5(5):799-
806. PubMed PMID: 33433263. Pubmed Central PMCID:
PMC8086530. Epub 2021/01/13. eng. |
|
| dc.citation |
12. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei
S, et al. Intravenous methylprednisolone pulse as a treatment
for hospitalised severe COVID-19 patients: results from
a randomised controlled clinical trial. The European respiratory
journal. 2020;56(6). PubMed PMID: 32943404. Pubmed Central
PMCID: PMC7758541 Epub 2020/09/19. eng. |
|
| dc.citation |
13. Aricò M, Danesino C, Pende D, Moretta L. Pathogenesis of
haemophagocytic lymphohistiocytosis. British journal of haematology.
2001;114(4):761-9. PubMed PMID: 11564062. Epub
2001/09/21. eng. |
|
| dc.citation |
14. Wang H, Ma S. The cytokine storm and factors determining
the sequence and severity of organ dysfunction in multiple organ
dysfunction syndrome. The American journal of emergency
medicine. 2008;26(6):711-5. PubMed PMID: 18606328. Epub
2008/07/09. eng. |
|
| dc.citation |
15. Awasthi S, Wagner T, Venkatakrishnan AJ, Puranik A, Hurchik
M, Agarwal V, et al. Plasma IL-6 levels following corticosteroid
therapy as an indicator of ICU length of stay in critically ill
COVID-19 patients. Cell death discovery. 2021;7(1):55. Pub-
Med PMID: 33723251. Pubmed Central PMCID: PMC7958587
Epub 2021/03/17. eng. |
|
| dc.citation |
16. Zielińska KA, Van Moortel L, Opdenakker G, De Bosscher
K, Van den Steen PE. Endothelial Response to Glucocorticoids
in Inflammatory Diseases. Frontiers in immunology.
2016;7:592. PubMed PMID: 28018358. Pubmed Central PMCID:
PMC5155119. Epub 2016/12/27. eng. |
|
| dc.citation |
17. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler
JA, et al. Dexamethasone treatment for the acute respiratory
distress syndrome: a multicentre, randomised controlled trial.
The Lancet Respiratory medicine. 2020;8(3):267-76. PubMed
PMID: 32043986. Epub 2020/02/12. eng. |
|
| dc.citation |
18. Zhang G, Wang J, Yao G, Shi B. Efficacy of high-dose methylprednisolone
pulse therapy in the treatment of enterovirus
71 encephalitis. Pakistan journal of pharmaceutical sciences.
2016;29(4 Suppl):1421-7. PubMed PMID: 27592493. Epub
2016/09/07. eng. |
|
| dc.citation |
19. Fujinaga S, Sakuraya K. Inhibitory effect of steroid on absorption
fever after percutaneous renal biopsy. Pediatrics international :
official journal of the Japan Pediatric Society. 2019;61(5):512-3.
PubMed PMID: 31099057. Epub 2019/05/18. eng. |
|
| dc.citation |
20. Vatti RR, Ali F, Teuber S, Chang C, Gershwin ME. Hypersensitivity
reactions to corticosteroids. Clinical reviews in allergy
& immunology. 2014;47(1):26-37. PubMed PMID: 23567983.
Epub 2013/04/10. eng. |
|
| dc.citation |
21. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW,
et al. Acute exacerbation of COPD. Respirology (Carlton, Vic).
2016;1(7):1152-65. PubMed PMID: 27028990. Pubmed Central
PMCID: PMC7169165. Epub 2016/03/31. eng. |
|
| dc.citation |
22. Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, Sancho-
López A, Mills-Sánchez P, Centeno-Soto GA, et al. A
Retrospective Controlled Cohort Study of the Impact of Glucocorticoid
Treatment in SARS-CoV-2 Infection Mortality. Antimicrobial
agents and chemotherapy. 2020;64(9). PubMed PMID:
32571831. Pubmed Central PMCID: PMC7449182. Epub
2020/06/24. eng. |
|
| dc.citation |
23. Selvaraj V, Dapaah-Afriyie K, Finn A, Flanigan TP. Short-Term
Dexamethasone in Sars-CoV-2 Patients. Rhode Island medical
journal (2013). 2020;103(6):39-43. PubMed PMID: 32570995.
Epub 2020/06/24. eng. |
|
| dc.citation |
24. Stockman LJ, Bellamy R, Garner P. SARS: systematic review
of treatment effects. PLoS medicine. 2006;3(9):e343. PubMed
PMID: 16968120. Pubmed Central PMCID: PMC1564166.
Epub 2006/09/14. eng. |
|
| dc.citation |
25. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK, et al. Severe
acute respiratory syndrome: report of treatment and outcome
after a major outbreak. Thorax. 2004;59(5):414-20. Pub-
Med PMID: 15115870. Pubmed Central PMCID: PMC1746995.
Epub 2004/04/30. eng. |
|
| dc.citation |
26. Hui DS. Systemic Corticosteroid Therapy May Delay Viral Clearance
in Patients with Middle East Respiratory Syndrome Coronavirus
Infection. American journal of respiratory and critical
care medicine. 2018;197(6):700-1. PubMed PMID: 29227752.
Epub 2017/12/12. eng. |
|
| dc.citation |
27. Wang J, Yang W, Chen P, Guo J, Liu R, Wen P, et al. The
proportion and effect of corticosteroid therapy in patients with
COVID-19 infection: A systematic review and meta-analysis.
PloS one. 2021;16(4):e0249481. PubMed PMID: 33882090.
Pubmed Central PMCID: PMC8059814. Epub 2021/04/22.
eng. |
|
| dc.citation |
28. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et
al. Dexamethasone in Hospitalized Patients with Covid-19. The
New England journal of medicine. 2021;384(8):693-704. Pub-
Med PMID: 32678530. Pubmed Central PMCID: PMC7383595.
Epub 2020/07/18. eng. |
|
| dc.citation |
29. Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fernández
J, Guirao Arrabal E, Colmenero Ruiz M, Ortego Centeno N.
Effectiveness of corticoid pulses in patients with cytokine storm
syndrome induced by SARS-CoV-2 infection. Medicina clinica.
2020;155(4):159-61. PubMed PMID: 32532461. Pubmed Central
PMCID: PMC7250763 patients. Epub 2020/06/14. eng |
|
| dc.citation |
30. López Zúñiga M, Moreno-Moral A, Ocaña-Granados A, Padilla-
Moreno FA, Castillo-Fernández AM, Guillamón-Fernández
D, et al. High-dose corticosteroid pulse therapy increases the
survival rate in COVID-19 patients at risk of hyper-inflammatory
response. PloS one. 2021;16(1):e0243964. PubMed PMID:
33507958. Pubmed Central PMCID: PMC7842890. Epub
2021/01/29. eng. |
|
| dc.citation |
31. Rana MA, Hashmi M, Qayyum A, Pervaiz R, Saleem M, Munir
MF, et al. Comparison of Efficacy of Dexamethasone and
Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-
19 Patients. Cureus. 2020;12(10):e10918. PubMed PMID:
33194485. Pubmed Central PMCID: PMC7657375. Epub
2020/11/17. eng. |
|
| dc.citation |
32. Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Krasnova
TN, Malahov PS, et al. Steroid pulse -therapy in patients
With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation
And Risk of vEnous thRombosis and thromboembolism
(WAYFARER Study). Kardiologiia. 2020;60(6):15-29. PubMed
PMID: 32720612. Epub 2020/07/29. eng |
|
| dc.citation |
33. Pinzón MA, Ortiz S, Holguín H, Betancur JF, Cardona Arango
D, Laniado H, et al. Dexamethasone vs methylprednisolone
high dose for Covid-19 pneumonia. PloS one.
2021;16(5):e0252057. PubMed PMID: 34033648. Pubmed
Central PMCID: PMC8148307. Epub 2021/05/26. eng. |
|
| dc.citation |
34. Pulakurthi YS, Pederson JM, Saravu K, Gupta N, Balasubramanian
P, Kamrowski S, et al. Corticosteroid therapy for COVID-
19: A systematic review and meta-analysis of randomized
controlled trials. Medicine. 2021;100(20):e25719. PubMed
PMID: 34011029. Pubmed Central PMCID: PMC8137023.
Epub 2021/05/21. eng. |
|
| dc.citation |
35. Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia
during the COVID-19 infection: What it shows and
what can be learned. Immunology letters. 2020;225:31-2. Pub-
Med PMID: 32569607. Pubmed Central PMCID: PMC7305732.
Epub 2020/06/23. eng. |
|
| dc.citation |
36. Zidar DA, Al-Kindi SG, Liu Y, Krieger NI, Perzynski AT, Osnard
M, et al. Association of Lymphopenia With Risk of Mortality
Among Adults in the US General Population. JAMA network
open. 2019;2(12):e1916526. PubMed PMID: 31790569. Pubmed
Central PMCID: PMC6902755 Epub 2019/12/04. eng. |
|
| dc.citation |
37. Liu J, Li H, Luo M, Liu J, Wu L, Lin X, et al. Lymphopenia
predicted illness severity and recovery in patients with
COVID-19: A single-center, retrospective study. PloS one.
2020;15(11):e0241659. PubMed PMID: 33206680. Pubmed
Central PMCID: PMC7673513. Epub 2020/11/19. eng. |
|